Literature DB >> 17159244

Criteria for malignancy in gastrointestinal endocrine tumors.

Cesare Bordi1, Tiziana D'Adda, Cinzia Azzoni, Silvia Pizzi, Lorena Bottarelli, Francesca Mormandi, Tommaso Antonetti, Tu Vinh Luong, Guido Rindi.   

Abstract

In contrast with the large amount of data generated from endocrine tumors of the pancreas, sparse and mostly unconfirmed data are available on the criteria for the assessment of malignancy risk and patient outcome in endocrine tumors of the gastrointestinal tract. In these conditions the 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded as useful for clinical purposes, providing the basis for proper management of the patients and for the design of treatment protocols. The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate. Three main categories, one further subdivided into two subgroups, are considered: (1) well-differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior; (2) well-differentiated endocrine carcinomas, low grade; and (3) poorly differentiated endocrine carcinomas, high grade. In this review the differential tumor characteristics between the different categories are summarized. Moreover, the relevance of additional features with respect to tumor prognostication, chiefly the Ki-67 proliferation index and malignancy-associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and of midgut origin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17159244     DOI: 10.1385/ep:17:2:119

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  46 in total

Review 1.  State of the art and future prospects in the management of neuroendocrine tumors.

Authors:  K Oberg
Journal:  Q J Nucl Med       Date:  2000-03

2.  Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization.

Authors:  E J Speel; J Richter; H Moch; C Egenter; P Saremaslani; K Rütimann; J Zhao; A Barghorn; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

Authors:  U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann
Journal:  Neuroendocrinology       Date:  2005-04-18       Impact factor: 4.914

Review 4.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

6.  Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors.

Authors:  A Barghorn; E J Speel; B Farspour; P Saremaslani; S Schmid; A Perren; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 7.  Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop.

Authors:  B Wiedenmann; R T Jensen; M Mignon; C I Modlin; B Skogseid; G Doherty; K Oberg
Journal:  World J Surg       Date:  1998-03       Impact factor: 3.352

8.  p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior.

Authors:  G Canavese; C Azzoni; S Pizzi; V D Corleto; C Pasquali; C Davoli; P Crafa; G Delle Fave; C Bordi
Journal:  Hum Pathol       Date:  2001-10       Impact factor: 3.466

9.  Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs).

Authors:  A Goto; T Niki; Y Terado; J Fukushima; M Fukayama
Journal:  Histopathology       Date:  2004-10       Impact factor: 5.087

10.  A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system.

Authors:  A Chaudhry; K Oberg; E Wilander
Journal:  Tumour Biol       Date:  1992
View more
  1 in total

Review 1.  Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors.

Authors:  Irina A Lubensky; Zhengping Zhuang
Journal:  Endocr Pathol       Date:  2007       Impact factor: 4.056

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.